Bruker Corporation 8-K SEC Filing Summary – Company Information, Address, and Securities Details (May 21, 2026)
Bruker Corporation (NASDAQ: BRKR) has released the results of its 2026 Annual Meeting of Stockholders held on May 21, 2026. Shareholders approved the election of directors, executive compensation, and the ratification of PricewaterhouseCoopers LLP as the independent auditor. These results indicate stable shareholder support for management and governance, though no extraordinary events were disclosed that would significantly impact the stock price in the short term.
Bruker (NASDAQ: BRKR) investors back board slate and auditor at 2026 meeting
Bruker Corporation (NASDAQ: BRKR) stockholders recently held their 2026 Annual Meeting, electing three Class II directors—Laura A. Francis, John J. (Jack) Phillips, and Hermann F. Requardt, Ph.D.—each for a three-year term. Shareholders also approved, on an advisory basis, the 2025 compensation for named executive officers and ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2026. These decisions reflect broad investor support for the company's existing leadership, executive compensation plan, and audit arrangements.
Thrivent Financial for Lutherans Acquires 152,603 Shares of Bruker Corporation $BRKR
Thrivent Financial for Lutherans significantly increased its stake in Bruker Corporation, acquiring an additional 152,603 shares to bring its total to 179,792 shares, valued at approximately $8.47 million. This comes as Bruker reported stronger-than-expected quarterly earnings and raised its FY 2026 guidance. Analysts currently have a "Hold" consensus rating on Bruker, with an average target price of $50.54.
Bruker (BRKR) director receives 2,886 RSUs vesting in 2027
Bruker Corp. director Bernard Thierry was granted 2,886 Restricted Stock Units (RSUs) as part of his compensation, which will vest entirely on May 15, 2027. These RSUs were issued at no cash cost and will convert to Bruker Common Stock shares upon vesting. This transaction is a routine equity award, increasing Thierry's direct holdings to 2,886 shares reflective of this grant.
Bruker (NASDAQ: BRKR) EVP exercises options and sells 2,000 shares under plan
Bruker Corporation's EVP and President of Bruker Nano Inc., Mark Munch, exercised stock options for 2,000 shares at $22.19 and subsequently sold 2,000 shares of common stock at $43.90 on May 15, 2026. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan. After the sale, Munch holds 128,443 shares of common stock and 8,000 stock options.
Bruker Corp stock (US1167941087): upbeat guidance and life-science demand support growth story
Bruker Corp has raised its growth outlook for 2025 and the mid-term due to strong demand for life-science and biopharma tools. The company specializes in high-end scientific instruments like mass spectrometry and NMR, capitalizing on trends in proteomics and precision medicine. While supported by recurring service revenues, its performance can be influenced by academic funding cycles and macroeconomic conditions.
2,000-share proposed sale via option exercise (BRKR) reported
A Form 144 notice reports a proposed insider sale of 2,000 shares of Bruker Corp (BRKR) common stock via a stock option exercise on May 15, 2026, with payment indicated as cash. The filing also details two previous sales of 2,000 shares each on April 15, 2026, and March 13, 2026, by Mark R Munch, generating proceeds of $79,800 and $70,880, respectively. Securities compliance and capital markets analysts view this as a neutral event with limited market impact due to the modest amounts involved.
Orbis group discloses 11.8% stake in Bruker Corp (BRKR)
Orbis Investment Management Ltd, Allan Gray Australia Pty Ltd, and Orbis Investment Management (U.S.), L.P. collectively own 17,940,076 shares of Bruker Corp (BRKR), representing an 11.8% stake. This information was disclosed in an amended Schedule 13G/A filing. Orbis Investment Management Ltd holds the majority of the sole voting and dispositive power for these shares.
Earnings Flash (BRKR) Bruker Corporation Posts Q1 Adjusted EPS $0.31 per Share, Vs. FactSet Est of $0.23
Bruker Corporation (BRKR) reported its Q1 adjusted EPS at $0.31 per share, significantly exceeding the FactSet estimate of $0.23 per share. This financial update highlights a stronger-than-expected performance for the quarter.
Stifel Maintains Bruker Corp(BRKR.US) With Hold Rating, Raises Target Price to $45
Stifel has reiterated its Hold rating on Bruker Corp (BRKR.US) and increased the target price to $45. This adjustment reflects the firm's continued assessment of Bruker's financial performance and market position, leading to a revised valuation.
Bruker Price Target Raised to $45.00/Share From $43.00 by TD Cowen
TD Cowen has increased its price target for Bruker shares to $45.00 from $43.00. This adjustment reflects an updated outlook on the company's valuation.
UBS Adjusts Price Target on Bruker to $45 From $40, Maintains Neutral Rating
UBS has increased its price target for Bruker (NASDAQ: BRKR) to $45, up from $40, while reaffirming a Neutral rating on the stock. This adjustment reflects a revised valuation outlook for the company by UBS analysts.
UBS Maintains Bruker Corp(BRKR.US) With Hold Rating, Raises Target Price to $45
UBS has reiterated its "Hold" rating on Bruker Corp (BRKR.US) and increased the target price to $45. This adjustment follows a recent analysis of the company's financial outlook.
A Quick Look at Today's Ratings for Bruker Corp(BRKR.US), With a Forecast Between $44 to $53
This article provides a summary of recent analyst ratings for Bruker Corp (BRKR.US), noting that analysts have assigned a price target range of $44 to $53 for the company. The report highlights that these ratings are critical for investors seeking insights into the anticipated future performance and valuation of the stock.
UBS Maintains Bruker Corp(BRKR.US) With Hold Rating, Raises Target Price to $45
UBS has reiterated its Hold rating on Bruker Corp (BRKR.US) while simultaneously increasing its target price for the stock to $45. This adjustment suggests a continued cautious but stable outlook on the company's performance by the analyst firm.
Opportunity Insights for the $1.1 Billion Preclinical Imaging Industry, 2026 - Bruker Corp., Cubresa, and Siemens Healthineers Lead
The global preclinical imaging market is projected to grow from $1.1 billion in 2026 to $1.7 billion by 2033, driven by increasing adoption of imaging techniques in drug discovery, translational research, and biomarker validation. Key drivers include advancements in imaging modalities, focus on personalized medicine, and rising R&D investments. North America leads the market, while Asia-Pacific is expected to experience the fastest growth, with Bruker Corp., Cubresa Inc., and Siemens Healthineers among the leading players.
TD Cowen Initiates Bruker Corp(BRKR.US) With Hold Rating, Announces Target Price $45
TD Cowen has initiated coverage on Bruker Corp (BRKR.US) with a "Hold" rating, setting a price target of $45. This new rating suggests that the analytical instruments and diagnostic solutions company's stock is expected to perform in line with the broader market. The target price provides investors with an indication of the firm's valuation perspective.
Q1 2026 Bruker Corp Earnings Call Transcript
This article provides the transcript of Bruker Corporation's (NAS:BRKR) first-quarter 2026 earnings conference call. It includes an introduction from Joe Kostka, Director of Investor Relations, highlighting the participation of President and CEO Frank Laukien and EVP and CFO Gerald Herman. The call also references a slide presentation available on Bruker's Investor Relations website and mentions the use of non-GAAP financial information with reconciliations.
Bruker Q1 Adjusted Earnings Fall, Revenue Rises; Maintains Fiscal 2026 Outlook
Bruker reported a decrease in Q1 adjusted earnings per share but an increase in revenue. Despite this, the company affirmed its fiscal 2026 financial outlook. This suggests Bruker anticipates future growth aligned with its long-term strategy.
FMR LLC boosts stake in Bruker (NASDAQ: BRKR) to 12.4%
FMR LLC has filed a Schedule 13G/A, disclosing a 12.4% beneficial ownership stake in Bruker (NASDAQ: BRKR), amounting to 19,208,582.41 shares of common stock. The filing indicates FMR LLC holds sole dispositive power over all these shares and sole voting power over 14,435,518.96 shares. This marks a passive institutional investment, with no other single entity reported to hold more than 5% interest.
Earnings call transcript: Bruker beats Q1 2026 forecasts, stock rises
Bruker Corporation (BRKR) reported strong first-quarter 2026 earnings, exceeding analyst expectations with an EPS of $0.31 against a forecast of $0.23 and revenue of $823.4 million, surpassing the anticipated $796.15 million. Despite a 4.4% organic revenue decline, the stock rose by 5.26% in premarket trading due to investor optimism and strategic cost-saving initiatives contributing to improved operating margins. The company also highlighted significant advancements in NMR and spatial biology innovation, and reconfirmed its full-year 2026 financial outlook, projecting continued growth and EPS expansion.
Opportunity Insights for the $1.1 Billion Preclinical Imaging Industry, 2026 - Bruker Corp., Cubresa, and Siemens Healthineers Lead
The preclinical imaging market is projected to grow from $1.1 billion in 2026 to $1.7 billion by 2033, driven by increased adoption in drug discovery, advancements in imaging technologies, and rising R&D investments. Key players like Bruker Corporation and Siemens Healthineers are leading this competitive market, with significant growth opportunities anticipated in emerging markets, particularly Asia-Pacific. The report highlights market drivers, business opportunities, regional analysis, and segmentation by product type, application, and end-user.
Full Transcript: Bruker Q1 2026 Earnings Call
Bruker (NASDAQ: BRKR) held its first-quarter 2026 earnings conference call, reporting revenues of $823 million, a 2.7% year-over-year increase, exceeding expectations despite headwinds. The company saw strong demand in AI-driven semiconductor metrology, European and Middle East security, and scientific software, leading to high single-digit organic growth in BSI bookings. Bruker reconfirmed its full-year 2026 guidance, projecting 4-5% reported revenue growth and 1-2% organic revenue growth, with significant margin expansion driven by cost-saving initiatives.
Bruker reports Q1 2026 revenue $823.4M, non-GAAP EPS $0.31; reaffirms FY26 guidance
Bruker reported its first-quarter 2026 financial results, with revenue reaching $823.4 million and non-GAAP diluted EPS at $0.31. The company reaffirmed its full-year 2026 guidance, expecting revenue between $3.57-$3.60 billion and non-GAAP EPS of $2.10-$2.15. Key highlights include strong organic bookings growth for Bruker Scientific Instruments and momentum in specific market segments like post-genomic research and AI-driven semiconductor metrology.
Bruker (NASDAQ: BRKR) Q1 2026 revenue rises 2.7% as FY26 outlook held
Bruker Corporation reported mixed Q1 2026 results with revenue rising 2.7% year-over-year to $823.4 million, though organic revenue declined 4.4%. Despite a drop in GAAP and non-GAAP EPS, the company reaffirmed its full-year 2026 financial guidance for revenue of $3.57 to $3.60 billion and non-GAAP EPS of $2.10 to $2.15, citing strong organic bookings growth in its Scientific Instruments segment. Management expects a return to organic revenue growth in Q2 2026.
Bruker: Q1 Earnings Snapshot
Bruker Corp. (BRKR) reported first-quarter earnings of $3.5 million, or 2 cents per share, which adjusted to 31 cents per share, exceeding Wall Street expectations. The scientific equipment maker posted revenues of $823.4 million, also surpassing forecasts. Despite solid Q1 results, Bruker's shares have declined 19% since the beginning of the year.
Bruker: Q1 Earnings Snapshot
Bruker Corp. (BRKR) reported first-quarter earnings of $3.5 million, or 2 cents per share, which adjusted to 31 cents per share, surpassed analyst expectations of 23 cents. The scientific equipment maker also exceeded revenue forecasts, posting $823.4 million against an estimated $800.1 million. Despite these Q1 results, Bruker's shares have seen a decline of 19% since the beginning of the year and nearly 7% over the last 12 months.
Bruker earnings on deck as first quarter results loom Wednesday
Bruker Corporation is set to announce its first-quarter 2026 financial results on Wednesday, May 6, 2026, with analysts anticipating a sequential decline in performance due to seasonal factors. Despite expected short-term headwinds, Wall Street maintains a "Buy" rating on Bruker stock, forecasting a 29% upside from current levels. Investors will be observing the impact of recent product launches, margin performance, and cost-saving initiatives to assess the company's ability to achieve its full-year growth and profitability targets.
Bruker earnings on deck as first quarter results loom Wednesday By Investing.com
Bruker (BRKR) is set to report its first-quarter 2026 financial results on Wednesday, May 6, 2026, before market open. Analysts anticipate a significant sequential decline in earnings and revenue due to seasonal factors, though Wall Street maintains a "Buy" rating on the stock with a projected 29% upside. Investors will be monitoring margin performance, cost-saving initiatives, and the impact of new product launches as the company aims for 4-5% revenue growth and margin expansion for the full year.
Earnings Preview: Bruker Corp to Report Financial Results Pre-market on May 06
This article announces that Bruker Corp (BRKR) is scheduled to release its financial results before market open on May 06. Analysts are expecting the company to report earnings of $0.62 per share. Investors will be keen to see if Bruker (BRKR) can surpass this estimate and provide positive guidance for the future.
Bruker Announces Date and Time of First Quarter 2026 Earnings Release and Webcast
Bruker Corporation (NASDAQ: BRKR) has announced that it will release its first quarter 2026 earnings after the market closes on Thursday, May 8, 2026. This will be followed by a webcast and conference call to discuss results and provide an updated outlook for 2026. The event is scheduled for 4:45 PM Eastern Time.
Analysts Estimate Bruker (BRKR) to Report a Decline in Earnings: What to Look Out for
Bruker (BRKR) is expected to report a year-over-year decline in earnings and lower revenues for the quarter ended March 2026, with an earnings estimate of $0.23 per share, down 51.1%. The stock's near-term price movement will heavily depend on how actual results compare to these expectations, though a negative Earnings ESP of -0.86% and a Zacks Rank #4 make a positive surprise less likely. Analysts have become more bearish recently, and the company has a mixed history of beating EPS estimates.
Bruker (BRKR) Expected to Announce Quarterly Earnings on Wednesday
Bruker (NASDAQ:BRKR) is scheduled to release its Q1 2026 earnings before market open on Wednesday, May 6th, with analysts anticipating earnings of $0.26 per share and revenue of $794.8090 million. The company previously reported Q4 earnings of $0.59 per share, missing consensus estimates, and analysts expect full-year EPS of $2 for both the current and next fiscal years. Bruker's stock performance, dividend announcement, recent analyst ratings, and insider activity are also detailed in the article.
Bruker (NASDAQ: BRKR) sets $3.9844 dividend on 6.375% preferred
Bruker Corporation announced a quarterly cash dividend of $3.9844 per share for holders of its 6.375% Mandatory Convertible Preferred Stock, Series A. The dividend was declared on April 28, 2026, and is payable on June 1, 2026, to shareholders of record as of May 15, 2026. This announcement was made through an 8-K filing, detailing the key figures and terms of the preferred dividend.
Universal Beteiligungs und Servicegesellschaft mbH Sells 135,470 Shares of Bruker Corporation $BRKR
Universal Beteiligungs und Servicegesellschaft mbH has decreased its stake in Bruker Corporation by selling 135,470 shares in the fourth quarter, now holding 437,694 shares valued at $20.79 million. Bruker missed Q4 EPS estimates but exceeded revenue expectations and provided strong FY2026 guidance. Analyst sentiment is mixed with a "Hold" rating, an average price target of $49.38, and a recent insider sale by its VP.
Bruker Announces Date and Time of First Quarter 2026 Earnings Release and Webcast
Bruker Corporation (Nasdaq: BRKR) has announced that it will release its first quarter 2026 financial results before market opening on Wednesday, May 6, 2026. The company will host a conference call and webcast at 8:00 a.m. Eastern Time to discuss these results and current business trends. Investors can access the webcast and pre-register for the call through Bruker's investor relations website.
Before the bell May 6: Bruker to post Q1 2026 results at 8 a.m. ET
Bruker Corporation (Nasdaq: BRKR) announced it will report its first quarter 2026 financial results before market opening on Wednesday, May 6, 2026. The company will host a conference call and webcast at 8:00 a.m. Eastern Time to discuss the results and current business trends. Investors can access the webcast and pre-register for the conference call through Bruker's investor relations website.
Bruker announces Q2 preliminary revenue between $795M and $798M; shares decline over 3.5%
Bruker Corporation announced preliminary Q2 revenue figures between $795 million and $798 million, falling short of their previous outlook of $820 million to $840 million and analyst expectations of $830 million. This news led to a decline of over 3.5% in the company's shares. Bruker attributes the shortfall primarily to weaker-than-expected academic and government research system orders, particularly in China.
Bruker Corp (BRKR) Stock Down 8.7% -- Now Undervalued? GF Score: 81/100
Shares of Bruker Corp (BRKR) dropped 8.7% to $36.22 on April 23, 2026, making the stock appear significantly undervalued with a GF Value™ of $71.52. Despite a strong GF Score™ of 81/100, indicating good overall performance and profitability, insider selling and lower financial strength scores suggest caution for potential investors. The company's current P/E of 17.1x is also well below its 5-year median, further reinforcing its undervaluation.
Bruker acquires Austria based biocrates
Bruker has announced the acquisition of Austria-based biocrates, a company specializing in metabolomics research and clinical proteomics kits. This acquisition aims to enhance Bruker's solutions for validated clinical research and molecular diagnostics, particularly in areas like heart disease, diabetes, and oncology.
Bruker unveils MyGenius PRO diagnostics system
Bruker's Microbiology & Infection Diagnostics division has launched its MyGenius PRO automated sample-to-answer (S2A) molecular diagnostics system in Europe, targeting infectious disease diagnostics. The system, developed in collaboration with ELITechGroup and Hitachi High-Tech, offers high throughput and automates the diagnostic workflow for immunocompromised patients, with an expanding menu of assays. This launch strengthens Bruker's molecular diagnostics portfolio and builds on recent success, as their Energy & Supercon Technologies division recently secured $500 million in MRI superconductor supply agreements.
Bruker Corp stock (US1167941087): Is its scientific instruments edge strong enough for steady growth
Bruker Corp, a key player in scientific instrumentation, provides high-precision tools for life sciences and materials research, benefiting from growing biotech and advanced manufacturing sectors. The company's business model, focused on recurring service contracts and continuous R&D, helps stabilize cash flow and foster innovation. Investors should consider Bruker's strong competitive position in niche high-tech instrumentation, its relevance to U.S. and English-speaking markets, and the balance of risks against secular growth drivers in science.
Bruker Corp stock (US1167941087): Is its scientific instruments edge strong enough for steady growth
Bruker Corp, a key player in scientific instrumentation, provides high-precision tools for life sciences and materials research, benefiting from growing biotech and advanced manufacturing sectors. The company's business model, focused on recurring service contracts and consumables, allows significant R&D investment and global market penetration. Analysts generally view Bruker's position favorably, highlighting its tech leadership and resilience, though risks include dependency on research funding and supply chain disruptions.
Bruker Launches MyGenius PRO® High-Throughput Sample-to-Answer Molecular Diagnostics System at ESCMID 2026
Bruker has launched its MyGenius PRO®, a high-throughput, fully automated molecular diagnostics system, at ESCMID Global 2026. Developed in collaboration with ELITechGroup and Hitachi High-Tech, this system automates the entire workflow from sample to result, enhancing efficiency for infectious disease diagnostics. It currently supports tests for CMV, EBV, and BKV, with rapid expansion planned for other viruses like HIV-1, HBV, and HCV throughout 2026.
Bruker Spatial Biology Showcases High Fidelity Spatial Data and Integrated Multi-platform Workflows for Unprecedented Multiomic Insights at AACR 2026
Bruker Spatial Biology is showcasing high-fidelity spatial data and integrated multi-platform workflows at the 2026 AACR Annual Meeting, aiming to provide deeper insights into oncology biology. Key announcements include new cross-platform workflows linking GeoMx DSP, CellScape XR, and CosMx SMI, along with the launch of the PaintScape platform for 3D genome visualization and new 208-plex datasets from CellScape XR. These advancements highlight Bruker's strategy to deliver best-in-class individual platforms that can be integrated for comprehensive multiomic analysis in cancer research.
Bruker Launches MyGenius PRO® High-Throughput Sample-to-Answer Molecular Diagnostics System at ESCMID 2026
Bruker has announced the European launch of its MyGenius PRO®, a fully automated, high-throughput, sample-to-answer molecular diagnostics system based on PCR technology, at ESCMID Global 2026. This system is designed for infectious disease diagnostics and automates the entire workflow from patient sample to diagnostic result, enhancing laboratory efficiency. Developed in collaboration with ELITechGroup and Hitachi High-Tech, the MyGenius PRO® will initially offer assays for CMV, EBV, and BKV, with rapid menu expansion planned throughout 2026.
Bruker unveils spatial biology workflows, opens PaintScape pre-orders
Bruker Corporation announced new spatial biology workflows and opened pre-orders for its PaintScape platform, which visualizes the 3D genome in single cells, at the 2026 American Association for Cancer Research Annual Meeting. The company also detailed extensions for its CellScape XR and CosMx SMI platforms, enhancing capabilities in spatial proteomics and whole transcriptome imaging. Despite a year-to-date stock decline, Bruker's stock is up nearly 8% over the past year and is considered undervalued by InvestingPro.
Bruker ties cancer research platforms together with new 208-plex data
Bruker Spatial Biology is showcasing new cross-platform workflows and 208-plex CellScape XR spatial proteomics datasets at AACR 2026, aiming to provide deeper insights into oncology biology. The company is launching new platforms like PaintScape for 3D genome visualization and CellScape XR for high-fidelity spatial proteomics, enhancing multiomic research capabilities. These advancements connect various spatial biology tools to accelerate translational research and biomarker discovery in cancer.
Bruker expands microbiology portfolio with new testing tools
Bruker Corporation announced significant enhancements to its microbiology and infection diagnostics portfolio, introducing new sample preparation kits, expanding reference libraries, and advancing automated systems under clinical evaluation. Despite its stock being down 17% year-to-date, the company is pursuing FDA submissions for new diagnostic claims in 2026 and integrating recently acquired pathogen diagnostics technology. InvestingPro data suggests the stock is currently undervalued.
Bruker rolls out PCR lab system for faster infection testing
Bruker (NASDAQ: BRKR) has launched MyGenius PRO®, a fully automated, high-throughput sample-to-answer molecular diagnostics system based on PCR technology, at ESCMID Global 2026. This system is designed for infectious disease diagnostics, offering continuous loading and random-access operation to enhance laboratory efficiency. Developed in collaboration with ELITechGroup (a Bruker company) and Hitachi High-Tech, the system initially offers assays for CMV, EBV, and BKV, with rapid expansion planned for other significant viruses like HIV-1 and HBV.
